早期自体干细胞移植背景下多发性骨髓瘤来那度胺或硼替佐米维持治疗的结局
该研究分析2010至2015年间577例接受早期自体移植的新诊断多发性骨髓瘤患者,其中341例未维持、132例用来那度胺、104例用硼替佐米维持。来那度胺维持较无维持改善无进展生存(中位37 vs 28个月),硼替佐米对全队列无获益但改善高危细胞遗传学亚组无进展生存。
要点
- 来那度胺维持较无维持改善无进展生存(中位37 vs 28个月,P=0.002)。
- 硼替佐米维持对全队列无进展生存无获益,但高危细胞遗传学亚组有改善。
- 来那度胺和硼替佐米因毒性停药分别见于17%和7%的患者。
核心结论
- 来那度胺或硼替佐米移植后维持治疗在临床实践中耐受良好,并改善多发性骨髓瘤高危亚组的无进展生存。
研究设计与样本
- 分析2010至2015年间接受早期自体移植的577例新诊断多发性骨髓瘤患者。
- 341例未接受维持治疗,132例接受来那度胺维持,104例接受硼替佐米维持。
主要发现
- 接受来那度胺或硼替佐米维持的患者高危细胞遗传学(荧光原位杂交)发生率更高:来那度胺组31% vs 硼替佐米组58% vs 无维持组8%(P<0.001)。
- 来那度胺维持较无维持改善无进展生存(中位37 vs 28个月,P=0.002;校正风险比0.48,95%CI 0.35-0.66)。
- 来那度胺维持改善ISS III期亚组无进展生存(中位40 vs 24个月,P=0.008)和高危细胞遗传学亚组无进展生存(中位27 vs 16个月,P=0.032)。
- 硼替佐米维持对全队列无进展生存无获益,但改善高危细胞遗传学亚组无进展生存(中位28 vs 16个月,P=0.035)。
- 来那度胺和硼替佐米维持因毒性停药分别见于17%和7%的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Post-transplant maintenance is widely used in multiple myeloma (MM); however, there is a lack of data on real-world outcomes. We have analyzed 577 patients with newly diagnosed MM undergoing early auto-transplantation between 2010 and 2015. A total of 341, 132 and 104 patients received no, lenalidomide (Len) or bortezomib (Bort) maintenance, respectively. Patients receiving Len or Bort maintenance had a higher incidence of high-risk cytogenetics by fluorescence in situ hybridization (31% (Len) vs 58% (Bort) vs 8% (No); P<0.001). Len maintenance led to a superior progression-free survival (PFS) compared with no maintenance (median, 37 vs 28 months, respectively; P=0.002; adjusted hazard ratio 0.48 (95% CI, 0.35-0.66)), including in subgroups with ISS stage III disease (median, 40 vs 24 months; P=0.008) and high-risk cytogenetics (median, 27 vs 16 months; P=0.032). Bort maintenance did not confer PFS benefit for the entire cohort, but improved PFS in the high-risk cytogenetic subgroup (median, 28 vs 16 months; P=0.035). Discontinuation due to toxicity was seen in 17 and 7% of patients receiving Len or Bort maintenance, respectively. Our results indicate that post-transplant maintenance with Len or Bort is well tolerated in clinical practice and improves PFS in high-risk subgroups of MM patients.
引用
- Chakraborty R, Muchtar E, Kumar SK, et al. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. Leukemia. 2017. PMID: 28848227. doi:10.1038/leu.2017.256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。